| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916127 | Nuclear Medicine and Biology | 2012 | 12 Pages |
Abstract
These results suggest that D2C7 warrants further evaluation for the development of MAb-based therapeutics against cancers expressing EGFRwt and EGFRvIII.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michael R. Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, Charles N. Pegram, Joanne Ayriss, Carol J. Wikstrand, Anne F. Buckley, Eric S. Lipp, James E. II, Roger E. McLendon, Darell D. Bigner,